3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide has been researched along with Disease Models, Animal in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basu, D; Dyck, B; Guest, K; Johnson, R; Mishra, RK; Sookram, C | 1 |
| Beyaert, MG; Daya, RP; Dyck, BA; Johnson, RL; Mishra, RK | 1 |
| Chang, M; Gabriele, J; Henry, P; Johnson, RL; Mishra, RK; Paladino, P; Saeedi, H; Sharma, S | 1 |
| Chugh, A; Johnson, RL; Marcotte, ER; Mishra, RK | 1 |
4 other study(ies) available for 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide and Disease Models, Animal
| Article | Year |
|---|---|
PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schi
Topics: Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Drug Administration Schedule; Interpersonal Relations; Male; MSH Release-Inhibiting Hormone; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Social Behavior Disorders | 2011 |
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Male; Motor Activity; Neostriatum; Nucleus Accumbens; Prefrontal Cortex; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia | 2013 |
Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
Topics: Administration, Oral; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans; Injections; Male; Mastication; MSH Release-Inhibiting Hormone; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Time Factors | 2003 |
Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Hormone Antagonists; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; MSH Release-Inhibiting Hormone; Nerve Degeneration; Neuroprotective Agents; Neurotoxins; Parkinson Disease, Secondary; Pyrrolidinones; Receptors, Dopamine | 1998 |